Published in Vaccine Weekly, January 31st, 2001
"Tumor cells fail to activate specific cytotoxic T lymphocytes due to lack of co-stimulatory molecules, e.g., CD80 (B7.1)," stated A.M. Kaufmann and colleagues, Loyola University, Illinois. "We were able to render cervical carcinoma cells immunogenic by introduction of the CD80 gene into the tumor cells. In order to enhance the efficiency of T-cell activation we investigated whether addition of interleukins would augment immunostimulation by CD80."
Kaufmann et al....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly